Go Pro
→ Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown” (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
+28.6%		$0.00
$0.00
▼
$0.44
$38K-9.0163,546 shs16,567 shs
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
$0.20
$0.38
$0.00
▼
$8.75
$350K0.581,299 shs456 shs
Predictive Technology Group, Inc. stock logo
PRED
Predictive Technology Group
$0.00
$0.00
▼
$0.04
$32K-0.7762,884 shsN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
$0.01
$0.01
$0.00
▼
$0.07
$69K1.445,100 shsN/A
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
+28.57%-30.77%-64.00%+800.00%-99.76%
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
0.00%+1,900.00%-57.89%-71.43%-97.21%
Predictive Technology Group, Inc. stock logo
PRED
Predictive Technology Group
0.00%0.00%0.00%0.00%0.00%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
0.00%+3.15%+3.15%+3.15%-64.88%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
+28.6%		$0.00
$0.00
▼
$0.44
$38K-9.0163,546 shs16,567 shs
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
$0.20
$0.38
$0.00
▼
$8.75
$350K0.581,299 shs456 shs
Predictive Technology Group, Inc. stock logo
PRED
Predictive Technology Group
$0.00
$0.00
▼
$0.04
$32K-0.7762,884 shsN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
$0.01
$0.01
$0.00
▼
$0.07
$69K1.445,100 shsN/A
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
+28.57%-30.77%-64.00%+800.00%-99.76%
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
0.00%+1,900.00%-57.89%-71.43%-97.21%
Predictive Technology Group, Inc. stock logo
PRED
Predictive Technology Group
0.00%0.00%0.00%0.00%0.00%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
0.00%+3.15%+3.15%+3.15%-64.88%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
1.00
SellN/AN/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
1.00
SellN/AN/A
Predictive Technology Group, Inc. stock logo
PRED
Predictive Technology Group
0.00
N/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$10.77M0.00N/AN/A($0.67) per share0.00
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
$400K0.89N/AN/A($6.04) per share-0.03
Predictive Technology Group, Inc. stock logo
PRED
Predictive Technology Group
N/AN/AN/AN/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/AN/AN/AN/A$10.50 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-$60.48M$0.730.00N/AN/A-254.28%N/A-192.17%11/5/2026 (Estimated)
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
-$28.92M-$19.15N/AN/AN/A-7,266.08%N/A-59.82%11/17/2026 (Estimated)
Predictive Technology Group, Inc. stock logo
PRED
Predictive Technology Group
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
-$40.16M-$5.31N/AN/AN/AN/A-248.33%-132.73%11/10/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/AN/AN/AN/AN/A
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
N/AN/AN/AN/AN/A
Predictive Technology Group, Inc. stock logo
PRED
Predictive Technology Group
N/AN/AN/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/A
0.48
0.48
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
N/A
1.71
1.71
Predictive Technology Group, Inc. stock logo
PRED
Predictive Technology Group
N/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/A
2.17
2.17

Institutional Ownership

CompanyInstitutional Ownership
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
44.27%
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
95.62%
Predictive Technology Group, Inc. stock logo
PRED
Predictive Technology Group
N/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
44.02%

Insider Ownership

CompanyInsider Ownership
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
6.90%
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
3.25%
Predictive Technology Group, Inc. stock logo
PRED
Predictive Technology Group
N/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
15.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
2041.85 million38.91 millionNo Data
Lyra Therapeutics, Inc. stock logo
LYRA
Lyra Therapeutics
501.77 million1.72 millionNo Data
Predictive Technology Group, Inc. stock logo
PRED
Predictive Technology Group
62316.67 millionN/ANot Optionable
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
605.23 million1.89 millionNot Optionable

Recent News About These Companies

Antibody Drug Conjugates (ADC) Market Research and Competitive Landscape Report 2026 - Extensive Analysis of Over 180 Companies and More Than 290 Drugs
April 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/antibody-drug-conjugates-adc-market-095100337.html
Contrasting Vincerx Pharma (NASDAQ:VINC) and iBio (NYSE:IBIO)
January 18, 2026  |  defenseworld.netD
Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders ...
July 16, 2025  |  gurufocus.comhttps://www.gurufocus.com/news/2982429/vincerx-pharma-inc-announces-additional-adjournment-of-special-meeting--urges-stockholders-to-vote-for-approval-of-dissolution-proposal--vinc-stock-news
Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal
July 16, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/16/3116827/0/en/Vincerx-Pharma-Inc-Announces-Additional-Adjournment-of-Special-Meeting-Urges-Stockholders-to-Vote-FOR-Approval-of-Dissolution-Proposal.html
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders | The ... - The Manila Times
July 9, 2025  |  manilatimes.netM
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - Morningstar
July 9, 2025  |  morningstar.comM
Vincerx Pharma, Inc. Common Stock (VINC) - Yahoo Finance
July 8, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/VINC/financials/
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders
July 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/07/3111291/0/en/Vincerx-Pharma-Inc-Urges-Stockholders-to-Vote-FOR-Approval-of-Dissolution-Proposal-and-Announces-Potential-Range-for-Distributions-to-Stockholders.html
Vincerx Pharma, Inc. (VINC) - Yahoo Finance
July 2, 2025  |  ca.finance.yahoo.comhttps://ca.finance.yahoo.com/quote/VINC/press-releases/
Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal
June 18, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/18/3101905/0/en/Vincerx-Pharma-Inc-Announces-Adjournment-of-Special-Meeting-Will-Reconvene-Meeting-on-July-16-2025-to-Secure-Votes-Needed-to-Approve-Dissolution-Proposal.html
Vincerx Pharma announces plan to delist from Nasdaq
April 18, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vincerx-pharma-announces-plan-to-delist-from-nasdaq-1034597516
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC
April 17, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/vincerx-pharma-inc-announces-intent-204500865.html
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC
April 17, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/17/3063864/0/en/vincerx-pharma-inc-announces-intent-to-delist-from-nasdaq-and-deregister-with-the-sec.html
Vincerx's final merger attempt collapses, leaving ADC biotech to wind down
April 9, 2025  |  fiercebiotech.comF
Vincerx terminates letter of intent with Global Digital, initiates wind down
April 9, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vincerx-terminates-letter-of-intent-with-global-digital-initiates-wind-down-1034562524
Financially struggling drugmaker's potential rescue falls apart. It now will wind down
April 9, 2025  |  bizjournals.comhttps://www.bizjournals.com/sanfrancisco/news/2025/04/08/cancer-vincerx-pharma-qumulusai-merger-fails.html
Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities
April 8, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/08/3057992/0/en/Vincerx-Pharma-Announces-Termination-of-Letter-of-Intent-and-Board-Authorization-to-Pursue-Wind-Down-Activities.html
Vincerx Pharma announces non-binding LOI for Qumulus AI combination
March 18, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vincerx-pharma-announces-non-binding-loi-for-qumulus-ai-combination-1034489795
Vincerx Pharma, Inc.: Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI
March 18, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-03/64858522-vincerx-pharma-inc-vincerx-pharma-announces-non-binding-letter-of-intent-for-business-combination-with-qumulusai-399.htm
Vincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisis
March 18, 2025  |  fiercebiotech.comF

New MarketBeat Followers Over Time

Top Headlines

View All Headlines
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
NVIDIA logo displayed on a computer chip surrounded by illuminated green circuit board traces.
NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
By Thomas Hughes | August 11, 2026
SoundHound AI logo displayed within a glowing orange ring against a dark background with light wave effects.
SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
By Thomas Hughes | August 10, 2026
Smartphone displaying the DraftKings logo beside a football, basketball, cash, and a neon Bet Live Now sign.
DraftKings’ Predictions Push Could Be the Bet That Matters Most
By Chris Markoch | August 12, 2026
Carisma Therapeutics stock logo

Carisma Therapeutics NASDAQ:CARM

$0.0009 +0.00 (+28.57%)
As of 09/3/2026 03:51 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Lyra Therapeutics stock logo

Lyra Therapeutics OTCMKTS:LYRA

$0.20 0.00 (0.00%)
As of 09/2/2026 11:09 AM Eastern

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Predictive Technology Group stock logo

Predictive Technology Group OTCMKTS:PRED

Predictive Technology Group, Inc., together with its subsidiaries, develops and commercializes discoveries and technologies involved in novel molecular diagnostic, therapeutic, and human cellular and tissue-based products (HCT/Ps). It operates in two segments, Human Cellular and Tissues Products (HCT/Ps); and Diagnostics and Therapeutics. The company provides FertilityDX, a genetic testing service for couples experiencing infertility; ARTguide, a genetic test for women experiencing infertility because of endometriosis and other genetic conditions; and regenerative medicine products, including AmnioCyte, AmnioCyte Plus, PolyCyte, and CoreCyte for use in regenerative medicine applications. It has a collaboration agreement with Atrin Pharmaceuticals LLC to develop molecular diagnostic tools to facilitate enhanced selection of cancer patients. The company was formerly known as Global Enterprises Group, Inc. and changed its name to Predictive Technology Group, Inc. in July 2015. Predictive Technology Group, Inc. was founded in 2005 and is headquartered in Salt Lake City, Utah. On November 9, 2023, Predictive Technology Group, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Utah. On January 12, 2024, the voluntary petition of Predictive Technology Group, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on November 9, 2023.

Vincerx Pharma stock logo

Vincerx Pharma NASDAQ:VINC

$0.01 0.00 (0.00%)
As of 09/2/2026

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas